List of FDA and Health Canada–approved immune checkpoint inhibitors and their indications.
| Name | Molecular Target | Indications |
|---|---|---|
| Ipilimumab | CTLA-4 | Metastatic melanoma |
| Nivolumab | PD-1 | Metastatic melanoma, NSCLC (squamous and n nonsquamous), renal cell carcinoma, Hodgkin lymphoma, SCCHN, urothelial carcinoma, HCC, dMMR and MSI-H colorectal cancer |
| Pembrolizumab | PD-1 | Metastatic melanoma, Hodgkin lymphoma, NSCLC, urothelial carcinoma, HNSCC, dMMR of MSI-H solid tumor, PD-L1 gastric and gastroesophageal junction adenocarcinoma |
| Atezolizumab | PD-L1 | Metastatic urothelial carcinoma, metastatic NSCLC |
| Avelumab | PD-L1 | Metastatic merkel cell carcinoma, urothelial carcinoma |
| Durvalumab | PD-L1 | Urothelial carcinoma, NSCLC |
| Cemiplimab | PD-1 | Squamous cell skin carcinoma |
| Combination ipilimumab + nivolumab | CTLA-4 + PD-1 | Metastatic melanoma, RCC, HNSCC, metastatic NSCLC with high PD-L1 expression |
FDA: US Food and Drug Administration; CTLA-4: T cell lymphocyte costimulation inhibitor; PD-1: programmed death protein-1; PD-L1: programmed death ligand-1; NSCLC: non small-cell lung carcinoma; RCC: renal cell carcinoma; SCCHN: squamous cell carcinoma of the head and neck; HCC: hepatocellular carcinoma; dMMR: mismatch repair deficient; MSI-H: microsatellite instability–high; HNSCC: head and neck squamous cell carcinoma.